Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sepracor, MedPointe To End Astelin Co-Promotion Agreement

This article was originally published in The Pink Sheet Daily

Executive Summary

The companies will continue to detail the product until June 30, then Sepracor will be responsible for sample coverage until the end of the year. Sepracor plans to focus sales efforts on in-house products.

You may also be interested in...



Swedish Specialty Pharma Meda Acquires MedPointe In $800 Million Transaction

Meda also acquires MedPointe’s 500-strong U.S. sales force in the deal.

Swedish Specialty Pharma Meda Acquires MedPointe In $800 Million Transaction

Meda also acquires MedPointe’s 500-strong U.S. sales force in the deal.

MedPointe Pumps Up The Volume On Astelin Marketing Campaign

Firm’s new marketing program for the nasal spray includes a direct-to-consumer advertising campaign and an increase in sales reps.

Related Content

Topics

UsernamePublicRestriction

Register

PS059293

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel